Anupam Rasayan India: Acquisition of equity shares of Bliss GVS Pharma Limited

What happened

Anupam Rasayan India (ANURAS) filed a disclosure with the exchanges on 29 September 2026 at 12:00 AM titled "Acquisition of equity shares of Bliss GVS Pharma Limited".

Company snapshot

Anupam Rasayan India is a small-cap company in the Chemicals sector, with a market value of about ₹13,515 crore.

The stock last traded at ₹1,187.1, against a 52-week range of ₹1,047.9–₹1,415 (16.1% below the high).

Before this filing the shares had moved −5.3% over the month and −5.7% over three months. Average daily turnover over the last 20 sessions was about ₹68.17 crore.

Promoters held 59.07% at the end of Q1 FY27; 21.79% of promoter shares were pledged. Foreign institutions owned 7.71% and domestic institutions 0.38%.

What history shows

BCEIE's records show 2 previous m&a filings from the company since May 2026.

Across 48 similar disclosures by other Chemicals companies, shares moved −1.2% on average the next day and −1.1% over five days; 31% of them rose the next day.

Market-wide, 1,921 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Regulatory approvals, completion of the deal and its effect on revenue and margins.

In the news

Recent coverage elsewhere (links open the original publisher):

• Anupam Rasayan India Share Price - Live NSE: ANURAS Stock Price & Chart — Upstox, 25 Sept 2026
• Anupam Rasayan share price falls 5% after NCD issue announcement | NCD size, other details here — TradingView, 21 Sept 2026
• Anupam Rasayan files draft offer for Bliss GVS — scanx.trade, 26 Sept 2026
• Volumes soar at Anupam Rasayan India Ltd counter — business-standard.com, 21 Sept 2026
• Anupam Rasayan India Stock Signals to Watch This Week — Univest, 23 Sept 2026

Source

• Exchange filing (PDF)